The IMTM’s mission is basic and translational biomedical research with the goal to understand the underlying causes of cancer and infectious diseases and to develop future human medicines and diagnostics. The formation of IMTM concentrates, formalizes and integrates the long-standing cooperation of the various research groups in the Czech Republic and abroad under one umbrella. Unique capabilities • The flexibility of our drug and biomarker discovery engine components to dynamically accommodate the project needs and create an optimal configuration is one of the greatest assets of the Institute. Strategically, it allows us as well as our academic and industrial partners to maximize drug and biomarker discovery resources for both exploratory and developmental projects. Industrial partners, especially large pharma can capitalize on such a flexible and adaptive research model that may be more difficult to practice in a large organization. • Cancer research expertise with cutting-edge technology platforms complemented with clinical oncology programs at the University Hospital in Olomouc and other collaborating hospitals. • Unique tissue/fluid biobanking complemented with clinical data. • IMTM is the national node for EATRIS (European Advance Translational Medicine Infrastructure), thus has access to wide range of European research institutions and hospitals performing translational research.